Hillsdale Investment Management Inc. Incyte Corp Transaction History

Hillsdale Investment Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$56.55 - $66.59 $11,310 - $13,318	-200 Reduced 2.35%	8,320 $473,000
Q4 2023 Feb 09, 2024	BUY	$52.16 - $64.19 $70,416 - $86,656	1,350 Added 18.83%	8,520 $534,000
Q3 2023 Nov 09, 2023	BUY	$57.77 - $65.93 $69,324 - $79,116	1,200 Added 20.1%	7,170 $414,000
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $6,095 - $7,551	100 Added 1.7%	5,970 $371,000
Q1 2023 May 10, 2023	BUY	$70.23 - $86.01 $400,311 - $490,257	5,700 Added 3352.94%	5,870 $424,000
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $11,420 - $14,298	170 New	170 $13,000
Q1 2022 Apr 28, 2022	BUY	$66.02 - $79.71 $11,883 - $14,347	180 New	180 $14,000
Q1 2020 May 12, 2020	SELL	$63.18 - $85.97 $6,949 - $9,456	-110 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$73.04 - $95.72 $8,034 - $10,529	110 New	110 $10,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.